WO2003085121A9 - Nucleic acid and corresponding protein entitled 213p1f11 useful in treatment and detection of cancer - Google Patents
Nucleic acid and corresponding protein entitled 213p1f11 useful in treatment and detection of cancer Download PDFInfo
- Publication number
- WO2003085121A9 WO2003085121A9 PCT/US2002/010220 US0210220W WO03085121A9 WO 2003085121 A9 WO2003085121 A9 WO 2003085121A9 US 0210220 W US0210220 W US 0210220W WO 03085121 A9 WO03085121 A9 WO 03085121A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- useful
- detection
- treatment
- nucleic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3015—Breast
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3038—Kidney, bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Hospice & Palliative Care (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Pregnancy & Childbirth (AREA)
- Gastroenterology & Hepatology (AREA)
- General Physics & Mathematics (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL16432602A IL164326A0 (en) | 2002-04-01 | 2002-04-01 | Nucleic acid and corresponding protein entitled 238p1b2 and pharmaceutical compositions containing the same |
PCT/US2002/010220 WO2003085121A2 (en) | 2002-04-01 | 2002-04-01 | Nucleic acid and corresponding protein entitled 213p1f11 useful in treatment and detection of cancer |
CA002480811A CA2480811A1 (en) | 2002-04-01 | 2002-04-01 | Nucleic acid and corresponding protein entitled 213p1f11 useful in treatment and detection of cancer |
EP02728647A EP1578980A4 (en) | 2002-04-01 | 2002-04-01 | Nucleic acid and corresponding protein entitled 213p1f11 useful in treatment and detection of cancer |
AU2002258689A AU2002258689C1 (en) | 2002-04-01 | 2002-04-01 | Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer |
IL164326A IL164326A (en) | 2002-04-01 | 2004-09-28 | Cancer-associated products and antibodies binding the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2002/010220 WO2003085121A2 (en) | 2002-04-01 | 2002-04-01 | Nucleic acid and corresponding protein entitled 213p1f11 useful in treatment and detection of cancer |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003085121A2 WO2003085121A2 (en) | 2003-10-16 |
WO2003085121A9 true WO2003085121A9 (en) | 2012-01-12 |
Family
ID=28789615
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/010220 WO2003085121A2 (en) | 2002-04-01 | 2002-04-01 | Nucleic acid and corresponding protein entitled 213p1f11 useful in treatment and detection of cancer |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1578980A4 (en) |
AU (1) | AU2002258689C1 (en) |
CA (1) | CA2480811A1 (en) |
IL (2) | IL164326A0 (en) |
WO (1) | WO2003085121A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040019915A1 (en) | 2002-04-01 | 2004-01-29 | Challita-Eid Pia M. | Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer |
GB0700133D0 (en) | 2007-01-04 | 2007-02-14 | Humabs Llc | Human cytomegalovirus neutralising antibodies and use thereof |
US7947274B2 (en) | 2007-01-04 | 2011-05-24 | Humabs, LLC. | Human cytomegalovirus neutralising antibodies and use thereof |
BRPI0916443A2 (en) | 2008-07-16 | 2017-10-31 | Inst Res Biomedicine | human cytomegalovirus neutralizing antibodies and their use |
CN114262683B (en) * | 2022-03-01 | 2022-06-17 | 中国科学院动物研究所 | Bacterial preparation for expressing VEGFR 3D 2 polypeptide and construction method and application thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4261297A (en) * | 1996-09-11 | 1998-04-02 | Incyte Pharmaceuticals, Inc. | Disease associated membrane protein (damp) |
US6432628B1 (en) * | 1997-08-26 | 2002-08-13 | Thomas Jefferson University | Caspase-14, an apoptotic protease, nucleic acids encoding and methods of use |
US6340740B1 (en) * | 1997-08-26 | 2002-01-22 | Thomas Jefferson University | Caspase-14, an apoptotic protease, nucleic acids encoding and methods of use |
IL140845A0 (en) * | 1998-07-14 | 2002-02-10 | Corixa Corp | Compositions for therapy and diagnosis of prostate cancer |
AU6502499A (en) * | 1998-10-02 | 2000-04-26 | Agensys, Inc. | Methods and compositions for the diagnosis and therapy of prostate cancer |
WO2001059110A2 (en) * | 2000-02-08 | 2001-08-16 | Agensys, Inc. | 34p3d7: a tissue specific protein highly expressed in prostate cancer |
US20020081705A1 (en) * | 2000-04-27 | 2002-06-27 | Mankovich John A. | Human caspase-14 compositions |
-
2002
- 2002-04-01 CA CA002480811A patent/CA2480811A1/en not_active Abandoned
- 2002-04-01 EP EP02728647A patent/EP1578980A4/en not_active Withdrawn
- 2002-04-01 AU AU2002258689A patent/AU2002258689C1/en not_active Ceased
- 2002-04-01 WO PCT/US2002/010220 patent/WO2003085121A2/en not_active Application Discontinuation
- 2002-04-01 IL IL16432602A patent/IL164326A0/en active IP Right Grant
-
2004
- 2004-09-28 IL IL164326A patent/IL164326A/en not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AU2002258689C1 (en) | 2008-04-24 |
IL164326A (en) | 2011-03-31 |
EP1578980A2 (en) | 2005-09-28 |
WO2003085121A2 (en) | 2003-10-16 |
AU2002258689B2 (en) | 2007-08-16 |
EP1578980A4 (en) | 2013-01-02 |
CA2480811A1 (en) | 2003-10-16 |
IL164326A0 (en) | 2005-12-18 |
AU2002258689A1 (en) | 2003-10-20 |
AU2002258689B8 (en) | 2003-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2003087306A8 (en) | Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer | |
AU2003243151A1 (en) | Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer | |
HK1152714A1 (en) | Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer steap-1 | |
EP1537140A4 (en) | Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer | |
AU2002318112B2 (en) | Nucleic acids and corresponding proteins useful in the detection and treatment of various cancers | |
AU2003232485A1 (en) | Neopeptides and methods useful for detection and treatment of cancer | |
EP1517606A4 (en) | Nucleic acid and corresponding protein entitled 193p1e1b useful in treatment and detection of cancer | |
EP1622571A4 (en) | Nucleic acids and corresponding proteins entitled 109p1d4 useful in treatment and detection of cancer | |
AU3510200A (en) | Human dickkopf-related protein and nucleic acid molecules and uses therefor | |
PT1537140E (en) | Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer | |
AU2002257050A1 (en) | Nucleic acid and corresponding protein entitled 125p5c8 useful in treatment and detection of cancer | |
EP1590437A4 (en) | Nucleic acids and corresponding proteins entitled 254p1d6b useful in treatment and detection of cancer | |
WO2002083916A8 (en) | Nucleic acid and corresponding protein entitled 162p1e6 useful in treatment and detection of cancer | |
AU2002246708A1 (en) | Nucleic acid and encoded zinc transporter protein entitled 108p5h8 useful in treatment and detection of cancer | |
AU2001285018A1 (en) | Nucleic acids and corresponding proteins entitled 83p2h3 and catrf2e11 useful in treatment and detection of cancer | |
EP1565200A4 (en) | Nucleic acid corresponding protein entitled 24p4c12 useful in treatment and detection of cancer | |
WO2003085121A9 (en) | Nucleic acid and corresponding protein entitled 213p1f11 useful in treatment and detection of cancer | |
AU2003268355A1 (en) | Localization of human cytomegalovirus nucleic acids and proteins in human cancer cells | |
AU2002254079A1 (en) | Nucleic acid and corresponding protein entitled 121p1f1 useful in treatment and detection of cancer | |
EP1545556A4 (en) | Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer | |
EP1499350A4 (en) | Nucleic acid and corresponding protein entitled 205p1b5 useful in treatment and detection of cancer | |
AU2003217112A1 (en) | Method and kit for detection of mutations in mitochondrial dna | |
AU2002305170A1 (en) | Nucleic acid and corresponding protein entitled 151p3d4 useful in treatment and detection of cancer | |
AU2001286541A1 (en) | Nucleic acids and corresponding proteins entitled phor1-a11 and phor1-f5d6 useful in treatment and detection of cancer | |
IL164390A0 (en) | Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2480811 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002728647 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002258689 Country of ref document: AU |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWP | Wipo information: published in national office |
Ref document number: 2002728647 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |